Immunotherapy in Ovarian Cancer:(IGWHC)-Lupine Publishers



Ovarian cancer ranks fifth with a 5-year survival of 40% for patients with advanced disease and remains the most lethal gynecologic malignancy among women [1]. Most patients with advanced disease undergo aggressive frontline treatments with surgery and adjuvant chemotherapy; however, 80% of patients ultimately recur within few months and develop chemoresistant disease [2]. Advances in traditional treatment regimens and addition bevacizumab as a targeted therapy have shown promising results with improved progression-free survival but overall survival rates still remains the unaltered.


For more Lupine Publishers Open Access Journals Please visit our website: http://www.lupinepublishers.com/

For more Healthcare Open Access Journal articles Please Click Here: http://www.lupinepublishers.com/gynecology-women-health-journal/

Comments

Popular posts from this blog

Factors Affecting Birth Weight of Newborns Among Neonates Born at Debre Markos Referral Hospital, Northwest Ethiopia

What is the role of Editors in Lupine Publishers?